Faculty Profile

Dr. Jonathan R. Lai, Ph.D.

Jonathan R. Lai, Ph.D.

Associate Professor, Department of Biochemistry

Professional Interests

 

Peptide and protein chemistry

Our group is broadly interested in the application of peptide, protein and antibody engineering methods for the discovery and development of novel immunotherapies and vaccines. Projects are highly interdisciplinary and involve aspects such as phage display, structure-based protein design, bispecific antibody engineering, structural biology, virology, and cancer biology. Current direction include:

1.     Engineered antibodies as virus immunotherapies. The use of monoclonal antibodies (mAbs) as therapeutics (immunotherapy) has been highly successful for oncology and other indications, but application of mAbs to viral immunotherapy is only now emerging. mAbs offer an advantage of being highly specific, with little adverse effects. Furthermore, mAbs can engage in Fc-related functions that may serve to promote clearance of infections. We have been using state-of-the-art protein engineering methods to identify, characterize, and evaluate novel virus immunotherapies against Ebola virus, Dengue virus, and Chikungunya virus. We focus on developing new therapeutics by protein engineering that may have features that are not possible with conventional (natural) antibodies.

2.     Immunogen design for flavivirus vaccine discovery. Dengue virus is a mosquito-transmitted flavivirus that causes hundreds of millions of human infections world-wide each year. There are four serotypes of Dengue (DENV1-4) that co-circulate in hyperendemic regions.  Dengue virus vaccine design has been complicated by the recent emergence of Zika virus (ZIKV), another flavivirus. We have been using structure-guided protein engineering to develop novel immunogens that elicit DENV and ZIKV protective antibody responses.  Our strategy focuses on common susceptible epitopes that may be structurally engineered.

3.     Dissection and engineering of protein-protein and protein-antibody interactions by phage display.  Phage display is a combinatorial technique that permits the selection of binding clones from highly diverse protein libraries.  We have used phage display to dissect critical determinants underlying specific protein-protein and protein-antibody interactions. Ultimately, this information can be utilized to design new proteins or antibodies with enhanced function; and contributes generally to our knowledge of protein recognition.  Projects focus on applications in T-cell immunology, chronic lymphocytic leukemia, and viral vaccine design.

 

Selected Publications

 Selected Recent Publications

Wec, A. Z.; Herbert, A. S.; Murin, C. D.; Nyakatura, E. K.; Abelson, D. M.; Fels, J. M.; He, S.; James, R. M.; de La Vega, M. A.; Zhu, W.; Bakken, R. R.; Goodwin, E.; Turner, H. L.; Jangra, R. K.; Zeitlin, L.; Qiu, X.; Lai, J. R.; Walker, L. M.; Ward, A. B.; Dye, J. M.*; Chandran, K.*; Bornholdt, Z. A.* Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.

Nyakatura, E. K.; Soare, A. Y.; Lai, J. R.* Bispecific Antibodies for Viral Immunotherapy. Hum. Vaccin. Immunother., 2017, 13, 836-842.

Wec,  A.Z.; Nyakatura, E. K.; Herbert, A. S.; Howell, K. A.; Holtsberg, F. W.; Bakken, R. R.; Mittler, E.; Christin, J. R.; Shulenin, S.; Jangra, R. K.; Bharrhan, S.; Kuehne, A. I.; Bornholdt, Z. A.; Flyak, A. I.; Saphire, E. O.; Crowe, J. E. Jr*, Aman, M. J.*, Dye, J. M.*, Lai, J. R.*, Chandran K.* A "Trojan horse" bispecific antibody strategy for broad protection against ebolaviruses. Science, 2016, 354, 350-354.

Frei, J. C.; Lai, J. R.* Protein and Antibody Engineering by Phage Display. Methods Enzymol., 2016, 580, 45-87.

Frei, J. C.; Nyakatura, E. K.; Zak, S. E.; Bakken, R. A.; Chandran, K.; Dye, J. M.*; Lai, J. R.*  Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.  Sci. Rep., 2016, 6, 19193.

Uchime, O.; Dai, Z.; Biris, N.; Lee, D.; Sidhu, S. S.; Li, S.; Lai, J. R.*; Gavathiotis, E.* Synthetic Antibodies Inhibit Bcl-2-associated X Protein (BAX) through Blockade of the N-terminal Activation Site.  J. Biol. Chem., 2016, 291, 89-102.

Frei, J. C.; Kielian, M.; Lai, J. R.* Comprehensive Mapping of Functional Epitopes on Dengue Virus Glycoprotein E DIII for Binding to Broadly Neutralizing Antibodies 4E11 and 4E5A by Phage Display. Virology, 2015, 485, 371-382.

Liu, Y.; Higgins, C. D.; Overstreet, C. M.; Rai, K. R.; Chiorazzi, N.*; Lai, J. R.*   Peptides that Bind Specifically to an Antibody form a Chronic Lymphocytic Leukemia Clone Expressing Unmutated Immunoglobulin Variable Region Genes.  Mol. Med., 2013, 19, 245-252.

More Information About Dr. Jonathan Lai

Lai Group Webpage

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Forchheimer Building, Room 320
Bronx, NY 10461

Tel: 718.430.8641
Fax: 718.430.8565

Research Information

In the News

Live Science interviews Dr. Jon Lai about his research engineering the first antibodies that can neutralize the most lethal strains of Ebola virus.

NY1 interviews Dr. Jonathan Lai about his research on Ebola that focuses on developing antibodies to use as a possible treatment for all five strains of the virus.

More media coverage